Clevudine

"目录号: HY-13859

Anti-infection-

Clevudine能抗乙肝病毒。

HBV

相关产品

Tenofovir Disoproxil Fumarate-Squalamine-Merimepodib-Entecavir monohydrate-Adefovir dipivoxil-Bay 41-4109-Bicyclol-Telbivudine-Osalmid-Helioxanthin 8-1-Helioxanthin derivative 5-4-2-Lagociclovir-Oxethazaine-

生物活性

Description

Clevudine is an antiviral drug for the treatment of hepatitis B. Target: HBVClevudine is a nucleoside analog with an unnatural beta-L configuration. Clevudine showed potent antiviral activity during therapy and induced a sustained posttreatment antiviral effect for 6 months after a 12-week treatment period, and this was associated with a sustained normalization of ALT levels [1]. Clevudine showed a potent antiviral response, and its effect was higher in HBeAg-negative patients, with rapid viral load reduction after therapy. However, long-term therapy for more than 1 year resulted in the development of considerable resistance and myopathy. Therefore, we should consider alternative antiviral agents if clevudine resistance or clevudine-induced myopathy is developed in patients on clevudine for the treatment of CHB [2].

Clinical Trial

NCT00558493

Bukwang Pharmaceutical

Chronic Hepatitis B

November 2007

Phase 4

NCT00044135

Triangle Pharmaceuticals

Hepatitis B

August 2002

Phase 2

NCT00823342

French National Agency for Research on AIDS and Viral Hepatitis-Gilead Sciences-Pharmasset

HBe Negative Chronic Hepatitis B-Hepatitis B Viral Infection

December 2008

Phase 3

NCT00558818

Bukwang Pharmaceutical

Chronic Hepatitis B

June 2007

Phase 4

NCT01264094

Bukwang Pharmaceutical

Chronic Hepatitis B

November 2009

Phase 4

NCT00362700

Bukwang Pharmaceutical

Hepatitis B

July 2003

Phase 2

NCT00672867

Bukwang Pharmaceutical

Patients With LC-B

December 2007

Phase 3

NCT00305019

Bukwang Pharmaceutical

Hepatitis B

July 2002

Phase 2

NCT00313287

Bukwang Pharmaceutical

Hepatitis B

June 2003

Phase 3

NCT00313274

Bukwang Pharmaceutical

Hepatitis B

July 2003

Phase 3

NCT00362505

Bukwang Pharmaceutical

Hepatitis B

June 2004

Phase 3

NCT01264354

Bukwang Pharmaceutical

Chronic Hepatitis B

March 2010

Phase 4

NCT01264133

Bukwang Pharmaceutical

Chronic Hepatitis B

September 2009

Phase 4

NCT01264367

Bukwang Pharmaceutical

HBeAg(+) Chronic Hepatitis B

December 2008

Phase 4

NCT01263002

Bukwang Pharmaceutical

Hepatitis B Associated Hepatocellular Carcinoma

June 2010

Phase 4

NCT00362635

Bukwang Pharmaceutical

Hepatitis B

August 2006

Phase 3

NCT00313261

Bukwang Pharmaceutical

Hepatitis B

June 2003

Phase 2

NCT00501124

Bukwang Pharmaceutical

Hepatitis B

May 2007

Phase 4

NCT01266005

Bukwang Pharmaceutical

Chronic Hepatitis B

August 2009

Phase 4

NCT00641082

Bukwang Pharmaceutical

HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

February 2008

Phase 4

NCT00798460

Inje University-Bukwang Pharmaceutical

Chronic Hepatitis B

December 2008

Phase 4

NCT01192854

Eisai Co., Ltd.-Eisai Inc.

Chronic Hepatitis B

February 2010

Phase 3

NCT00496158

Pharmasset

Chronic Hepatitis-Hepatitis B

August 2007

Phase 3

NCT00496002

Pharmasset

Chronic Hepatitis-Hepatitis B

August 2007

Phase 3

NCT01581242

Bukwang Pharmaceutical

Healthy

April 2012

Phase 1

NCT01712815

University of Southern California-National Cancer Institute (NCI)

HER2-positive Breast Cancer-Recurrent Breast Cancer-Stage IA Breast Cancer-Stage IB Breast Cancer-Stage II Breast Cancer-Stage IIIA Breast Cancer-Stage IIIB Breast Cancer-Stage IIIC Breast Cancer-Stage IV Breast Cancer

November 22, 2013

View MoreCollapse

References

[1].Lee, H.S., et al., A 12-week clevudine therapy showed potent and durable antiviral activity in HBeAg-positive chronic hepatitis B. Hepatology, 2006. 43(5): p. 982-8.

[2].Jang, J.H., et al., Clevudine for chronic hepatitis B: antiviral response, predictors of response, and development of myopathy. J Viral Hepat, 2011. 18(2): p. 84-90.

你可能感兴趣的:(Clevudine)